AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: AMY REEVES
In the age of terrorism, it's perhaps not the biggest weapons that give people nightmares. It's the smallest.
The mysterious appearance of the poison ricin in Sen. Bill Frist's office recently reminded us of how easily biological agents can slip into seemingly secure locations. And thanks to new medical technologies, it's even easier to manipulate poisons and viruses into potent weapons.
To help combat the threat, the Department of Homeland Security and other federal agencies are making deals with biotechs to help develop biodefense products.
Some are working on vaccines and treatments for possible weapons such as anthrax, ricin and plague. Others are developing detectors to catch these substances before they reach their victims.
President Bush's proposed Project BioShield, now working its way through Congress, would provide $5.6 billion over the next 10 years to help in the bioterrorism fight.
Dr. Russell Gilbertson, a former medical doctor and immunology specialist who's now a financial analyst for Roth Capital Partners, has been studying biotech companies that work on biodefense.